Does SIMVASTATIN Cause Malignant neoplasm progression? 40 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Malignant neoplasm progression have been filed in association with SIMVASTATIN (Simvastatin). This represents 0.2% of all adverse event reports for SIMVASTATIN.
40
Reports of Malignant neoplasm progression with SIMVASTATIN
0.2%
of all SIMVASTATIN reports
5
Deaths
27
Hospitalizations
How Dangerous Is Malignant neoplasm progression From SIMVASTATIN?
Of the 40 reports, 5 (12.5%) resulted in death, 27 (67.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SIMVASTATIN. However, 40 reports have been filed with the FAERS database.
What Other Side Effects Does SIMVASTATIN Cause?
Myalgia (3,919)
Fatigue (2,066)
Arthralgia (1,775)
Drug interaction (1,744)
Nausea (1,676)
Rhabdomyolysis (1,616)
Dyspnoea (1,542)
Headache (1,470)
Drug hypersensitivity (1,433)
Muscular weakness (1,356)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which SIMVASTATIN Alternatives Have Lower Malignant neoplasm progression Risk?
SIMVASTATIN vs SINGULAIR
SIMVASTATIN vs SINTILIMAB
SIMVASTATIN vs SIPONIMOD
SIMVASTATIN vs SIPULEUCEL-T
SIMVASTATIN vs SIROLIMUS